|
| 36347013 | Genetic basis and molecular profiling in myeloproliferative neoplasms. | Blood | 2023 |
| 36814396 | Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms. | Am J Hematol | 2023 |
| 35015307 | PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. | Am J Hematol | 2022 |
| 36053947 | Co-expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness. | Am J Hematol | 2022 |
| 34983928 | Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. | Nat Commun | 2022 |
| 32814349 | Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera. | Blood | 2021 |
| 33623882 | Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. | Hemasphere | 2021 |
| 33761144 | Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. | Am J Hematol | 2021 |
| 33707020 | Multimodality imaging beyond CLEM: Showcases of combined in-vivo preclinical imaging and ex-vivo microscopy to detect murine mural vascular lesions. | Methods Cell Biol | 2021 |
| 34333533 | High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells. | Blood Cancer J | 2021 |
| 33241558 | 5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines. | Arch Pharm (Weinheim) | 2021 |
| 33202418 | Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor. | Blood | 2021 |
| 31123029 | High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. | Haematologica | 2020 |
| 32014125 | Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. | Lancet Haematol | 2020 |
| 31741139 | Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. | Int J Hematol | 2020 |
| 33134869 | Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups. | Hemasphere | 2020 |
| 32824053 | Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis. | Cancers (Basel) | 2020 |
| 32326377 | STAT5 is Expressed in CD34[+]/CD38[-] Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. | Cancers (Basel) | 2020 |
| 31471561 | Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. | Leukemia | 2020 |
| 30635286 | CDK6 coordinates <i>JAK2</i> <sup><i>V617F</i></sup> mutant MPN via NF-κB and apoptotic networks. | Blood | 2019 |
| 31064751 | Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. | Blood | 2019 |
| 31133746 | MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. | Nat Genet | 2019 |
| 30902807 | Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. | Blood | 2019 |
| 30535576 | International external quality assurance of JAK2 V617F quantification. | Ann Hematol | 2019 |
| 28744014 | Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. | Leukemia | 2018 |
| 30074634 | Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. | Hematol Oncol | 2018 |
| 29907599 | Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. | Blood | 2018 |
| 30287855 | Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. | Blood Cancer J | 2018 |
| 30333916 | Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. | Oncotarget | 2018 |
| 30442766 | LZTR1 is a regulator of RAS ubiquitination and signaling. | Science | 2018 |
| 29472722 | Chromothripsis in acute myeloid leukemia: biological features and impact on survival. | Leukemia | 2018 |
| 27432009 | Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. | Br J Haematol | 2017 |
| 29153976 | Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. | Lancet Haematol | 2017 |
| 29089570 | Parallel genome-wide screens identify synthetic viable interactions between the BLM helicase complex and Fanconi anemia. | Nat Commun | 2017 |
| 28914569 | Mutations in myeloproliferative neoplasms - their significance and clinical use. | Expert Rev Hematol | 2017 |
| 28028029 | Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. | Blood | 2017 |
| 26845587 | Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. | J Innate Immun | 2016 |
| 28725479 | A time-resolved molecular map of the macrophage response to VSV infection. | NPJ Syst Biol Appl | 2016 |
| 26574608 | Germline RBBP6 mutations in familial myeloproliferative neoplasms. | Blood | 2016 |
| 26423830 | Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. | Blood | 2016 |
| 26668133 | Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. | Blood | 2016 |
| 26608331 | Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. | Blood | 2016 |
| 27149854 | A Comprehensive Analysis of the Dynamic Response to Aphidicolin-Mediated Replication Stress Uncovers Targets for ATM and ATMIN. | Cell Rep | 2016 |
| 27389715 | Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. | Blood | 2016 |
| 27191495 | The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. | Oncotarget | 2016 |
| 27216218 | LNK mutations in familial myeloproliferative neoplasms. | Blood | 2016 |
| 27401344 | Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. | J Exp Med | 2016 |
| 27569099 | 8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls. | J BUON | 2016 |
| 26987905 | Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. | Leukemia | 2016 |
| 26883579 | Thrombopoietin receptor is required for the oncogenic function of CALR mutants. | Leukemia | 2016 |